drugset
drugset / Trial / NCT04440280

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280 ↗

Phase 2 Recruiting 45 enrolled Massachusetts Eye and Ear Infirmary
RandomizedParallel-groupDouble-blindTreatment

Summary

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

Timeline

Start
2020-09-16
Primary completion
2026-04-29
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 10 % Topical
Comparator N-acetylcysteine Small molecule 20 % Topical

Indications

Fuchs' endothelial dystrophy